Great question! There have been some exciting developments in generalized myasthenia gravis (gMG) treatments recently. Here's a look at the newer FDA-approved options:
Targeted Therapies (Newer Approvals)
- Efgartigimod (Vyvgart/Vyvgart Hytrulo) — an FcRn blocker that reduces harmful antibodies
- Rozanolixizumab Show Full Answer
Great question! There have been some exciting developments in generalized myasthenia gravis (gMG) treatments recently. Here's a look at the newer FDA-approved options:
Targeted Therapies (Newer Approvals):
- Efgartigimod (Vyvgart/Vyvgart Hytrulo) — an FcRn blocker that reduces harmful antibodies
- Rozanolixizumab (Rystiggo) — approved for AChR or MuSK antibody-positive gMG, also available as a subcutaneous infusion
- Zilucoplan (Zilbrysq) — a complement inhibitor approved specifically for AChR antibody-positive gMG
- Nipocalimab (Imaavy) — a newly FDA-approved FcRn blocker, notable for being approved for the broadest population of gMG patients As for how they're being accepted — about 15% of MGteam members in a recent poll reported using these newer targeted therapies. While traditional treatments like pyridostigmine and corticosteroids remain the most common, that 15% is still a meaningful number.
These newer treatments tend to be used when:
- Traditional treatments aren't controlling symptoms well enough
- Side effects from older medications are difficult to tolerate
- A person's antibody type (AChR or MuSK) makes them a good candidate
It's worth noting that some of these treatments are only approved for specific antibody types, so knowing your antibody status is really important when exploring options with your specialist.
August 26
Join
Your Privacy Choices
